Therapy News and Research

RSS

Celulas Genetica to submit international patent application for Rutherford Procedure

Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.

10 Dec 2010

Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency

Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.

10 Dec 2010

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

Opinions: Questioning WHO's relevance; Reforming foreign aid; Efforts to prevent child marriage

"The WHO - for 62 years the world's go-to agency on all public health matters - is today outmoded, underfunded, and overly politicized," Jack Chow, former assistant director-general on HIV/AIDS, tuberculosis and malaria at WHO, writes in a Foreign Policy Argument where he outlines some of the major issues facing the WHO, including personnel challenges, the agency's "archaic" governance system and a "new atmosphere, where [other] organizations are taking health into their own hands."

10 Dec 2010

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

The long-awaited results of the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer, the AZURE trial, will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 8-12.

10 Dec 2010

Physiotherapy Associates announces new MS Specialty Program

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, announced its new MS Specialty Program, which includes physical therapy services and a health and wellness program designed to reduce or alleviate the symptoms of MS for patients, available in its more than 600 clinics throughout the United States.

10 Dec 2010

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA can prevent it.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

New software may help improve major deficiencies in ADHD children

An intensive, five-week working memory training program shows promise in relieving some of the symptoms of attention deficit hyperactivity disorder in children, a new study suggests.

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

9 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

Firefly enzyme offers new medical imaging agent for blood clot detection

The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.

9 Dec 2010

Trauma surgeon co-authors call to action to establish pediatric trauma research network

Jeffrey S. Upperman, MD, director of the Trauma Program at Children's Hospital Los Angeles, has co-authored a call to action for filling a significant gap in pediatric public health care and seeks federal oversight to establish the framework for a pediatric applied trauma research network (PATRN). This call to action was published simultaneously in the Journal of Pediatric Surgery and the Journal of Trauma.

9 Dec 2010

Insulin related calls to poison centers increase 279%

Annual calls to poison centers regarding insulin have skyrocketed by 279 percent over the past 10 years, according to a new study authored by medical professionals at four U.S. poison centers.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Therapy News and Research

Celulas Genetica to submit international patent application for Rutherford Procedure

Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

Opinions: Questioning WHO's relevance; Reforming foreign aid; Efforts to prevent child marriage

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

Physiotherapy Associates announces new MS Specialty Program

Silencing the TLR4 gene can prevent cardiovascular disease in diabetic patients

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

New software may help improve major deficiencies in ADHD children

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Expert discusses androgen deprivation therapy for prostate cancer

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Firefly enzyme offers new medical imaging agent for blood clot detection

Trauma surgeon co-authors call to action to establish pediatric trauma research network

Insulin related calls to poison centers increase 279%

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News